Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Approach to treatment: ventricular rate control
- Is this rate control (example)
- Tachycardia induces cardiomyopathy
- Rate control of AF with exercise
- AFFIRM study
- RACE II trial (1)
- RACE II trial (2)
- Rate control – the bottom line
- Approach to treatment: sinus rhythm maintenance
- Is sinus rhythm needed?
- Outpatient cardioversion of atrial arrhythmias
- ACC/AHA guidelines
- Amiodarone for sinus rhythm
- ATHENA: dronedarone
- PALLAS: dronedarone
- Antiarrhythmic medical therapies
- Pulmonary veins can trigger AF
- Pulmonary veins trigger AF: simplified concept
- Atrial fibrillation is complex
- AF - various lesion sets
- AF ablation - potential risks
- Ablation vs. drugs: the A4 study
- Ablation vs. antiarrhythmic drugs
- Worldwide AF ablation survey
- AF ablation - success rates
- Meta-analysis: 4 randomized trials
- Efficacy of catheter ablation for AF
- Ablation AF: patient selection recommendations
- AF ablation – any downside?
- Where does ablation fit in?
- Rhythm control – the bottom line
- Rhythm control – the future
- Back to our patient
- Bottom line for the average AF patient
Topics Covered
- Approach to treatment
- Rate control in AF
- Is sinus rhythm needed?
- ACC/AHA guidelines – Rhythm control: data from clinical trials
- Pulmonary veins can trigger AF
- AF ablation
- Ablation vs. drugs
Talk Citation
Olshansky, B. (2015, October 29). Atrial fibrillation - management, the challenge and new solutions 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 23, 2024, from https://doi.org/10.69645/ATDY6700.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Brian Olshansky has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Atrial fibrillation - management, the challenge and new solutions 2
Published on October 29, 2015
29 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:04
Let's consider
another important issue
with regard to
the management of patients
with atrial fibrillation
and that is
ventricular rate control.
0:15
Here is a Holter monitor
of a patient
who had apparent rate control.
At about 1 o'clock
in the afternoon,
this patient came to clinic
and was found
to have a heart rate
of about 80 beats a minute.
A Holter monitor was applied
and as you can see here,
over the next ensuing day,
the heart rate fluctuated
throughout the day
and became quite fast
during some points in time.
This could explain symptoms,
it could explain
cardiomyopathy development,
it could explain the fact
that rate control alone
may not be effective in terms
of symptomatic management
or management
of atrial fibrillation at all.
So what is adequate rate control
is a hard thing to define.
But it really means
that the patients
generally have heart rates
in the physiologic range
that would be expected
for that individual
at a specific point in time
and that is
yet to be better defined
because some of the data
would suggest that that rate
should be in the 80 beat
per minute range
and other data would suggest
it should be
even higher than that.
1:19
We showed several years ago,
that rapid rates, especially
from ventricular tachycardias,
especially
from atrial fibrillation,
can cause a cardiomyopathy.
And this tachycardia-induced
cardiomyopathy
which develops slowly
due to rapid rates
can lead to heart failure.
And it's partially reversible,
but over time it can lead
to remodeling of the heart
and can lead
to the risk of sudden death.
This is something
you do not want to have,
this is something
that may be avoidable
by adequate rate control
in atrial fibrillation.
So what are the data
in terms
of randomized controlled
clinical trials
that show benefit
in terms of rate control?